Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A number of longevity biotech startups have sprung up, such as Senisca in Exeter, Genflow Biosciences in London, and Shift Bioscience and clock.bio in Cambridge. In the US, the pack is led by California firms such as Altos Labs, which also has a research institute in Cambridge, Calico, backed by Google’s owner Alphabet, Unity Biotechnology and Retro Biosciences.
“We punch way above our weight in terms of the quality and the quantity of our scientific output in the ageing space,” said Lorna Harries, professor of molecular genetics at the University of Exeter, who set up the spinout Senisca in 2020. “But while we’re a scientific powerhouse, we need to develop our ability to turn our findings into things that are tangible outcomes in the real world.”
British biotech races US’s ‘buff billionaires’ for secret of eternal youth
The UK excels at ‘longevity research’. Could it become part of an industry that fascinates the wealthiest people in the world?
Rns looks good
can see some billionaire takes this out soon
already Jeff Bazoz looking into this sector.
yes Jeff Bazoz
Huge RNS!! Well done to everyone
0 0 0
Let's hope Eric has a wad of positive newsflow to deliver in the coming days and weeks...Gla holders...On and UP!!! ;-)
North east you got the rns
HUGE funding grant vs mkt cap
This could really go somewhere
Well done holders
C'mon Eric, let's make 2024 a "Bright" one!!! Tick Tock. Gla ;-)
Totally agree! We needs the RNS now
This company needs to stop beating round the bush and give an RNS that is directly relevant to research and tell us how it is progressing.
Taken from LinkedIn, this notes that Genflow are involved in a programme which has just received €10m non dilutive grant funding, for a gene therapy programme from the Belgian government via Wallonia:
GT4Health, an ambitious project focussed on gene therapy and led by the 5 universities of the FWB, was selected as part of the Win4Excellence program of Wallonia!
🧬 Thanks to funding of more than 10 million euros, researchers wish to develop disruptive strategic research in gene therapy, for a holistic strengthening of Wallonia internationally and the sustainability of its value chain.
This research, coordinated by Géraldine Piel, is also a beautiful illustration of the collaborations between the academic world, accredited research centres (CER Group) and industrialists, since several companies are associated with the project: UCB, GenFlow Biosciences, Exothera and QUALIblood s.a.
🤝 For the assembly of this major project, the researchers were also able to count on the support and valuable collaboration of the KTOs of the LiEU Network.
At UMONS, the services of Cell Biology | Lionel Tafforeau & Systems, Estimation, Command and Optimisation (SECO) | Laurent Dewasme and Alain Vande Wouwer are involved. Two doctoral theses will be funded: a first in the SECO service, which will aim at the development of digital twins of AAV (adeno associated virus) production processes in order to optimise their culture conditions, and a second in co-supervision with ULB, which will focus on the development of innovative solutions to optimise genome editing in human haematopoietic stem cells (HSC), intended for gene therapy of primary immunodeficiencies.
GenFlow Biosciences
1,411 followers
17m
With the New Year in full swing, it's easy to want to cheat on any goals you may have set for prolonging your #healthspan. Check out what this article by a Harvard nutrition expert about a few simple ways you can eat for longevity 🧬 “Longevity, of course, is influenced by many factors,” says Dr. Frank B. Hu, a professor of nutrition and epidemiology at the Harvard T.H. Chan School of Public Health.“But diet is one of the most important factors that can impact chronic disease risk, mortality and longevity.”
Read more here: hTtps://loom.ly/Ir5B7vA #GenFlowBiosciences #ageing #GENF
Hot off the press, €8.1m awarded to PDC , so hopefully Genflow's next on the list.
https://www.businesswire.com/news/home/20240117630349/en/PDC*line-Pharma-and-Partners-Receive-%E2%82%AC8.1M-From-Walloon-Region-and-Wallonia-Health-Cluster-BioWin-for-Personalized-Therapeutic-Vaccine-Project
So much huge game changing news that’s due. Also mention of a new program in the Guardian newspaper the other week.
This share is incredibly undervalued!
Thanks for posting it from the Telegram group ( I'm not a member) all very encouraging for the delivery of some very good news.
0 0 0
Eric confirmed in his August/September interview that Genflow are in negotiation for two non-dilutive research grants which would provide funds for 80% of their R & D for an additional 3 years, fully cashed well into 2026, and so confrmation news in the pipeline along with an update on their Werner Syndrome accelerated clinical plans highly likely. Gl :-)
Evening Money.
I can’t take the credit for that. Someone else found it.
All very promising. Hopefully now the news can drop.
GLA
Nice on Northeast, a great find and thanks for posting. Excitement building. Gl :-)
The Company is headquartered in London and has a Belgian R&D subsidiary, Genflow Biosciences SRL (“Genflow BE”) that was established in 2020. Genflow BE’s location enables it to benefit from the relatively low operating costs and from substantial (non diluting) grants that support its research and development that are available from Belgium’s Wallonia region.
In addition to pre-clinical activities, Genflow seeks an earlier path to revenue with respect to Werner Syndrome, a rare progressive disorder characterised by the appearance of unusually accelerated ageing.
Genflow intends to conduct a European Phase I/II clinical trial with Werner Syndrome patients. The Company believes that positive clinical data will be the source of significant value creation through, potential acquisition or licensing arrangements. Moreover, a trial in Werner Syndrome will support the path to a specific aging indication.
Partners:
University of Liège | Free University of Brussels - LME | ULG -CORD | CER Group | Revatis | GenFlow Biosciences | QUALITY ASSISTANCE S.A. | UNIVERCELLS | Kaneka Belgium NV | Eurogentec | UCB | BIOPHARMA | Henogen S.A. | UCLouvain - Catholic University of Leuven (TRAIL) - @PILAB | UCL - IMCN/BSMA | UCL -IREC | ULB-BCTL | LiveDrop | salamanderU | PDC*line Pharma | Orgenesis Belgium | DNAlytics | CELYNTRA THERAPEUTICS | OncoDNA | PharmaLex | UCL -LFEM | ULB -CMMI | UMONS - CMMI | XOMEXBIO | Vésale Bioscience | NOVADIP Biosciences S.A. | EXOBIOLOGIC | CYLIX GROUP |
just been posted on telegram! genf mentioned
*************c/1547827892/1748
as part of the wallonia recovery plan, the walloon government is launching an innovation partnership dedicated to atmps (innovative therapy drugs) with a budget of €81 million - 60% public money and 40% private business funds - over 3 years, in collaboration with the biowin cluster - the health cluster of wallonia and the public service of wallonia.
🔬 the partnership involves 26 partners and aims to maintain leadership and strengthen the sector in wallonia by establishing new collaborations between academic partners, a research centre and companies of all sizes.
💊 advanced therapy drugs are new generation biomedicines aimed at meeting unmet medical needs (breast and colorectal cancer, solid tumours, liver fibrosis, central nervous system pathologies...). they represent one of the most innovative and promising revolutions in modern medicine.
👩🏻🔬👨🏼🔬it is estimated that more than 470 direct and 1,200 indirect jobs will be created in the next five years. the atmp sector in wallonia already represents 6,000 direct and indirect jobs.
the atmp pit is a unique opportunity for the development and growth of a sector of importance for the future of wallonia.
Ps the Estee Lauder connection is very interesting and potentially very exciting considering Genflow's GF-3001 for Werner Syndrome ( premature ageing disease ) is a Topical delivery of Sirt6 directly to the skin, and so endless opportunities and potential in all aspects of age reversal. Gla :-)
Cheers Northeast, anytime now and hopefully the start of a great year ahead for all invested as positive newsflow is delivered, and yes indeed Porter, any association with Estee Lauder's longevity aspirations involving Sirtuin R&D can only be a good thing for Genflow going forward. C'mon Eric , ready when you are!!! ;-)
It is reassuring to see giants like Estée Lauder working on innovative skincare with Genflow’s own advisors and collaborative partners.
Not long now until the world economic forum meets, where it is expected longevity will be amongst the key topics under discussion, with a better focus globally on the work that companies like Genflow are achieving.
Evening Money!
Great posts as always. As the long wait here continues, I’m sure news will land any day now. For certain. Funding grants and new projects!
GL
Interestingly enough, Estee Lauder's new longevity product is the patented Sirtivity-LP technology, and appear to be investing heavily into the longevity space. Gla ;-)
From January 2024, the Estée Lauder Longevity Collective will serve as a brand advisory board, bringing new insights, research findings and resources to inform the brand’s ongoing approach to skin longevity research.
Collective members include Dr Nadine Pernodet, the brand’s Senior Vice President, Bioscience, Global R&D; long-term Estée Lauder partner Dr Danica Chen, Professor of Metabolic Biology, Nutritional Sciences & Toxicology at the University of California Berkeley; and Serena Liang Jing, a ‘New Map of Life’ Fellow at the Stanford Center on Longevity.
Experts from the Buck Institute for Research on Aging, the Center of Aging Research & Clinical Care at Weill Cornell Medicine, and the Stanford University School of Medicine will also be involved.
Next month will further see Estée Lauder launch Re-Nutriv Ultimate Diamond Transformative Brilliance Soft Crème.
The new sku is made with the brand’s patented Sirtivity-LP technology, which reveals visible age reversal starting at 14 days of use.
It is said to be the result of two decades of Estée Lauder’s study into the role of sirtuins – commonly known as ‘longevity proteins’ – in skin.
“The Estée Lauder brand has always been at the forefront of skin science,” said Justin Boxford, Global Brand President, Estée Lauder.
https://cosmeticsbusiness.com/est%C3%A9e-lauder-targets-age-reversal-with-stanford-center
The Future Is Bright
To a certain extent, the things you can do now to prevent premature aging is to live a healthy lifestyle that limits stress, follow a healthy diet, exercise regularly, and so on.
Fortunately, the future’s looking bright with medical biotechnological advancements.
Genflow Biosciences works with major anti-aging research centers across the globe and believes that the SIRT6 gene is a master regulator of managing healthy aging and the potential therapeutic target preserve function.
These discoveries are in pursuit of finding disruptive anti-aging drugs. In fact, clinical testing is starting to happen, albeit in the infancy stages, making way for potentially transformative medicines.
hTtps://genflowbio.com/premature-aging/